2024
Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract
Li J, Dong Y, Chen F, Yang H, Chen P, Li H, Shi S, Zhou X, Zhu L, Zhang Y, Liu L, Xie X, Yu F, Jin J, Lv J, Zhang H. Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by Lactobacillus casei cell wall extract. Frontiers In Immunology 2024, 15: 1368322. PMID: 38558821, PMCID: PMC10978756, DOI: 10.3389/fimmu.2024.1368322.Peer-Reviewed Original ResearchCell wall extractsLactobacillus casei cell wall extractBiomarkers of kidney dysfunctionComplement activationFactor H mutationSeverity of glomerular lesionsPositive rate of IgAMild kidney damageDecline of kidney functionPathogenesis of IgA nephropathyProduction of IgA.Wall extractsGlomerular IgA depositionPathogenesis of IgANWild type controlsComplement overactivationElevated IgAElevated biomarkersHeterozygous mutationsC57BL/6 miceIgA-IgGKidney dysfunctionAlternative pathwayComplement inhibitorsIgA nephropathy
2023
Chemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitorsHomeostatic, Non-Canonical Role of Macrophage Elastase in Vascular Integrity
Salarian M, Ghim M, Toczek J, Han J, Weiss D, Spronck B, Ramachandra A, Jung J, Kukreja G, Zhang J, Lakheram D, Kim S, Humphrey J, Sadeghi M. Homeostatic, Non-Canonical Role of Macrophage Elastase in Vascular Integrity. Circulation Research 2023, 132: 432-448. PMID: 36691905, PMCID: PMC9930896, DOI: 10.1161/circresaha.122.322096.Peer-Reviewed Original ResearchConceptsMMP-12 deficiencyAdverse aortic remodelingAbdominal aortic aneurysmAng IIAortic remodelingAortic aneurysmMMP-12Complement component 3 levelsNeutrophil extracellular traps markersAbdominal aortic aneurysm ruptureAortic aneurysm ruptureElastic lamina degradationPlasma complement componentsAortic ruptureC3 levelsComplement depositionPlasma C5aMore neutrophilsVascular remodelingAneurysm ruptureNeutrophil elastaseAortic integrityMatrix metalloproteinaseComplement inhibitorsNETosis pathway
2021
An update: the emerging evidence of complement involvement in COVID-19
Li Q, Chen Z. An update: the emerging evidence of complement involvement in COVID-19. Medical Microbiology And Immunology 2021, 210: 101-109. PMID: 33811541, PMCID: PMC8019074, DOI: 10.1007/s00430-021-00704-7.Peer-Reviewed Original ResearchConceptsAcute respiratory distress syndromeCOVID-19 patientsCOVID-19Pre-clinical samplesRespiratory distress syndromePotential treatment optionCoronavirus disease 2019Host immune responseMultiorgan failureComplement involvementSystemic inflammationDistress syndromeSevere patientsOrgan damageKidney failureTreatment optionsInflammatory responseTissue injuryDisease 2019Immune responseAnimal modelsMultiple organsAbnormal activationInnate immunityComplement inhibitors
2020
Consistent improvement with eculizumab across muscle groups in myasthenia gravis
Mantegazza R, O'Brien F, Yountz M, Howard J, Mazia C, Wilken M, Barroso F, Saba J, Rugiero M, Bettini M, Chaves M, Vidal G, Garcia A, De Bleecker J, Van den Abeele G, de Koning K, De Mey K, Mercelis R, Mahieu D, Wagemaekers L, Van Damme P, Depreitere A, Schotte C, Smetcoren C, Stevens O, Van Daele S, Vandenbussche N, Vanhee A, Verjans S, Vynckier J, D’Hont A, Tilkin P, de Siqueira Carvalho A, Brockhausen I, Feder D, Ambrosio D, César P, Melo A, Ribeiro R, Rocha R, Rosa B, Veiga T, da Silva L, Engel M, Geraldo J, da Penha Ananias Morita M, Coelho E, Paiva G, Pozo M, Prando N, Torres D, Butinhao C, Duran G, Fialho T, da Silva T, Gonçalves L, Pazetto L, Volpe L, Duca L, Friedrich M, Guerreiro A, Mohr H, Martins M, da Cruz Pacheco D, Ferreira L, Macagnan A, Pinto G, de Cassia Santos A, Oliveira A, de Andrade A, Annes M, Silva L, Lino V, Pinto W, Assis N, Carrara F, Miranda C, Souza I, Fernandes P, Siddiqi Z, Phan C, Narayan J, Blackmore D, Mallon A, Roderus R, Watt E, Vohanka S, Bednarik J, Chmelikova M, Cierny M, Toncrova S, Junkerova J, Kurkova B, Reguliova K, Zapletalova O, Pitha J, Novakova I, Tyblova M, Jurajdova I, Wolfova M, Andersen H, Harbo T, Vinge L, Krogh S, Mogensen A, Vissing J, Højgaard J, Witting N, Autzen A, Pedersen J, Erälinna J, Laaksonen M, Oksaranta O, Harrison T, Eriksson J, Rozsa C, Horvath M, Lovas G, Matolcsi J, Szabo G, Jakab G, Szabadosne B, Vecsei L, Dezsi L, Varga E, Konyane M, Antonini G, Di Pasquale A, Garibaldi M, Morino S, Troili F, Fionda L, Pasquale A, Evoli A, Alboini P, D’Amato V, Iorio R, Inghilleri M, Fionda L, Frasca V, Giacomelli E, Gori M, Lopergolo D, Onesti E, Frasca V, Gabriele M, Saccà F, Filla A, Costabile T, Marano E, Fasanaro A, Marsili A, Puorro G, Antozzi C, Bonanno S, Camera G, Locatelli A, Maggi L, Pasanisi M, Campanella A, Uzawa A, Kanai T, Kawaguchi N, Mori M, Kaneko Y, Kanzaki A, Kobayashi E, Murai H, Masaki K, Matsuse D, Matsushita T, Uehara T, Shimpo M, Jingu M, Kikutake K, Nakamura Y, Sano Y, Utsugisawa K, Nagane Y, Kamegamori I, Tsuda T, Fujii Y, Futono K, Ozawa Y, Mizugami A, Saito Y, Samukawa M, Suzuki H, Morikawa M, Kamakura S, Miyawaki E, Okumura M, Funaka S, Kawamura T, Nakamori M, Takahashi M, Taichi N, Hasuike T, Higuchi E, Kobayashi H, Osakada K, Shiraishi H, Miyazaki T, Motomura M, Mukaino A, Yoshimura S, Asada S, Yoshida S, Amamoto S, Kobashikawa T, Koga M, Maeda Y, Takada K, Takada M, Tsurumaru M, Yamashita Y, Suzuki Y, Akiyama T, Narikawa K, Tano O, Tsukita K, Kurihara R, Meguro F, Fukuda Y, Sato M, Imai T, Tsuda E, Shimohama S, Hayashi T, Hisahara S, Imai T, Kawamata J, Murahara T, Saitoh M, Shimohama S, Suzuki S, Yamamoto D, Ishiyama Y, Ishiyama N, Noshiro M, Takeyama R, Uwasa K, Yasuda I, van der Kooi A, de Visser M, Gibson T, Kim B, Lee C, Koo Y, Seok H, Kang H, Ra H, Kim B, Bin Cho E, Choi M, Lee H, Min J, Seok J, Lee J, Koh D, Kwon J, Park S, Choi E, Hong Y, Ahn S, Koo D, Lim J, Shin C, Hwang J, Kim M, Kim S, Jeong H, Jung J, Kim Y, Lee H, Shin H, Hwang E, Shin M, Casasnovas C, Aguilo M, Homedes‐Pedret C, Palacios N, Porras L, Santamaria V, Lazaro A, Carbonell J, Sune P, Figueras M, Gili G, Mazuela G, Illa I, Vicente E, Diaz‐Manera J, Gutiérrez L, Garcia R, Vidal N, Arribas‐Ibar E, Tejedor E, Salcedo P, Fernandez‐Fournier M, Ruiz P, de Rivera F, Fernandez‐Fournier M, Sastre M, Piehl F, Hietala A, Bjarbo L, Sengun I, Meherremova A, Ozcelik P, Balkan B, Tuga C, Ugur M, Erdem‐Ozdamar S, Bekircan‐Kurt C, Acar N, Yilmaz E, Caliskan Y, Orsel G, Efendi H, Aydinlik S, Cavus H, Kutlu A, Becerikli G, Semiz C, Tun O, Terzi M, Dogan B, Onar M, Sen S, Cavdar T, Veske A, Norwood F, Dimitriou A, Gollogly J, Mahdi‐Rogers M, Seddigh A, Sokratous G, Maier G, Sohail F, Jacob S, Sadalage G, Torane P, Brown C, Shah A, Sathasivam S, Arndt H, Davies D, Watling D, Amato A, Cochrane T, Salajegheh M, Roe K, Amato K, Toska S, Wolfe G, Silvestri N, Patrick K, Zakalik K, Katz J, Miller R, Engel M, Forshew D, Bravver E, Brooks B, Sanjak M, Plevka S, Burdette M, Cunningham S, Kramer M, Nemeth J, Schommer C, Scott T, Juel V, Guptill J, Hobson‐Webb L, Massey J, Beck K, Carnes D, Loor J, Anderson A, Pascuzzi R, Bodkin C, Kincaid J, Snook R, Guingrich S, Micheels A, Chaudhry V, Corse A, Mosmiller B, Kelley A, Ho D, Srinivasan J, Vytopil M, Jara J, Ventura N, Carter C, Donahue C, Herbert C, Scala S, Weiner E, Alam S, McKinnon J, Haar L, McKinnon N, Alcon K, McKenna K, Sattar N, Daniels K, Jeffery D, Freimer M, Hoyle J, Kissel J, Agriesti J, Chelnick S, Mezache L, Pineda C, Muharrem F, Karam C, Khoury J, Marburger T, Kaur H, Dimitrova D, Gilchrist J, Agrawal B, Elsayed M, Kohlrus S, Ardoin A, Darnell T, Golden L, Lokaitis B, Seelbach J, Muppidi S, Goyal N, Sakamuri S, So Y, Paulose S, Pol S, Welsh L, Bhavaraju‐Sanka R, Gonzalez A, Dishman L, Jones F, Gonzalez A, Padilla P, Saklad A, Silva M, Nations S, Trivedi J, Hopkins S, Kazamel M, Alsharabati M, Lu L, Nozaki K, Mumfrey‐Thomas S, Woodall A, Mozaffar T, Cash T, Goyal N, Roy G, Mathew V, Maqsood F, Minton B, Jones H, Rosenfeld J, Garcia R, Echevarria L, Garcia S, Pulley M, Aranke S, Berger A, Shah J, Shabbir Y, Smith L, Varghese M, Shabbir Y, Gutmann L, Gutmann L, Jerath N, Nance C, Swenson A, Olalde H, Kressin N, Sieren J, Barohn R, Dimachkie M, Glenn M, McVey A, Pasnoor M, Statland J, Wang Y, Liu T, Emmons K, Jenci N, Locheke J, Fondaw A, Johns K, Rico G, Walsh M, Herbelin L, Hafer‐Macko C, Kwan J, Zilliox L, Callison K, Young V, DiSanzo B, Naunton K, Benatar M, Bilsker M, Sharma K, Cooley A, Reyes E, Michon S, Sheldon D, Steele J, Karam C, Traub R, Chopra M, Vu T, Katzin L, McClain T, Harvey B, Hart A, Huynh K, Beydoun S, Chilingaryan A, Doan V, Droker B, Gong H, Karimi S, Lin F, McClain T, Polaka K, Shah A, Tran A, Akhter S, Malekniazi A, Tandan R, Hehir M, Waheed W, Lucy S, Weiss M, Distad J, Strom S, Downing S, Kim B, Bertorini T, Arnold T, Henderson K, Pillai R, Liu Y, Wheeler L, Hewlett J, Vanderhook M, Nowak R, Dicapua D, Keung B, Kumar A, Patwa H, Robeson K, Yang I, Nye J, Vu H. Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals Of Clinical And Translational Neurology 2020, 7: 1327-1339. PMID: 32700461, PMCID: PMC7448154, DOI: 10.1002/acn3.51121.Peer-Reviewed Original ResearchConceptsAnti-acetylcholine receptorOpen-label extensionMyasthenia Gravis ActivitiesMyasthenia gravisDaily Living ProfileMuscle groupsLiving ProfilesDomain scoresOpen-label extension trialQuantitative myasthenia gravis scalePhysician-reported outcomesTerminal complement inhibitorEculizumab treatmentExtension trialMuscle strengthSustained improvementPatientsGravisComplement inhibitorsREGAIN studyTotal scoreTreatment elicitsRapid improvementPlaceboEculizumab
2018
Novel and preclinical treatment strategies in pneumococcal meningitis
Bewersdorf J, Grandgirard D, Koedel U, Leib S. Novel and preclinical treatment strategies in pneumococcal meningitis. Current Opinion In Infectious Diseases 2018, 31: 85-92. PMID: 29095719, DOI: 10.1097/qco.0000000000000416.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPneumococcal meningitisNew adjuvant therapiesSystematic clinical testingProtein-based pneumococcal vaccinesPreclinical treatment strategiesPneumococcal conjugate vaccineAnti-inflammatory therapyImprove disease outcomesToxic bacterial productsMatrix metalloproteinase inhibitorsNonbacteriolytic antibioticsAdjuvant dexamethasoneLife-threatening diseaseMeningeal inflammationBacterial meningitisSerotype replacementTreatment optionsConjugate vaccinePneumococcal vaccineMorbidity rateComplement inhibitorsTreatment strategiesSuppress inflammationMeningitis
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashion
1994
Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection.
Fodor W, Williams B, Matis L, Madri J, Rollins S, Knight J, Velander W, Squinto S. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proceedings Of The National Academy Of Sciences Of The United States Of America 1994, 91: 11153-11157. PMID: 7526391, PMCID: PMC45185, DOI: 10.1073/pnas.91.23.11153.Peer-Reviewed Original ResearchConceptsHuman complement inhibitorsHyperacute rejectionComplement inhibitorsAnti-porcine antibodiesTerminal complement inhibitorTransgenic pigsXenogeneic transplantation modelPorcine cell typesHigh-level cell surface expressionVariety of murineXenogeneic complementsXenogeneic organ transplantationGraft failureOrgan rejectionVessel occlusionCell surface expressionHyperacute organ rejectionTransplantation modelOrgan transplantationXenogeneic organsVascular endotheliumTransgenic miceSerum complementAutologous complementTransplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply